Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Expenses (2016 - 2025)

Tg Therapeutics has reported Operating Expenses over the past 10 years, most recently at $142.1 million for Q4 2025.

  • Quarterly results put Operating Expenses at $142.1 million for Q4 2025, up 81.6% from a year ago — trailing twelve months through Dec 2025 was $493.0 million (up 71.72% YoY), and the annual figure for FY2025 was $493.0 million, up 71.72%.
  • Operating Expenses for Q4 2025 was $142.1 million at Tg Therapeutics, up from $132.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for TGTX hit a ceiling of $142.1 million in Q4 2025 and a floor of $35.1 million in Q3 2022.
  • Median Operating Expenses over the past 5 years was $75.2 million (2022), compared with a mean of $78.3 million.
  • Biggest five-year swings in Operating Expenses: plummeted 59.78% in 2022 and later skyrocketed 85.24% in 2025.
  • Tg Therapeutics' Operating Expenses stood at $95.3 million in 2021, then fell by 18.53% to $77.6 million in 2022, then dropped by 27.27% to $56.5 million in 2023, then soared by 38.58% to $78.2 million in 2024, then surged by 81.6% to $142.1 million in 2025.
  • The last three reported values for Operating Expenses were $142.1 million (Q4 2025), $132.3 million (Q3 2025), and $106.3 million (Q2 2025) per Business Quant data.